Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120

Vaccine

Volumn 16, Issue 19, 1998, Pages 1803-1811

  Pinter, A ^a   Honnen, W J ^a   Kayman, S C ^a   Trochev, O ^a   Wu, Z ^a,b  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

gp120; Human immunodeficiency virus type 1 (HIV 1); V1 V2 domain

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HYBRID PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C108G; MONOCLONAL ANTIBODY C311E; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY TITER; CONFERENCE PAPER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; RAT; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CHO CELLS; CHROMATOGRAPHY, AFFINITY; CRICETINAE; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PHENOTYPE; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS;

EID: 0032210842     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00182-0     Document Type: Conference Paper

References (54)

1. 1 Matthews, T. J. Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. AIDS Res. Hum. Retroviruses 1994, 10, 631-632.
2. 2 Golding, H., D'Souza, M. P., Bradac, J., Mathieson, B. and Fast, P. Neutralization of HIV-1: Meeting report. AIDS Res. Hum. Retroviruses 1994, 10, 633-643.
3. 3 D'Souza, M. P., Milman, G. and Bradac, J. A. et al. Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies. AIDS 1995, 9, 867-874.
4. 4 Moore, J., Cao, Y. and Qing, L. et al. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 1995, 69, 101-109.
5. 5 Kostrikis, L. G., Cao, Y., Ngai, H., Moore, J. P. and Ho, D. D. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J. Virol. 1996, 70, 445-458.
6. 6 Moore, J. P., Cao, Y., Leu, J., Qin, L, Korber, B. and Ho, D. D. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J. Virol. 1996, 70, 427-444.
7. 7 Javaherian, K., Langlois, A. J. and McDanal, C. et al. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 6768-6772.
8. 8 Tilley, S. A., Honnen, W. J., Racho, M. E., Hilgartner, M. and Pinter, A. A human monoclonal antibody against the CD4 binding site of HIV-1 gp120 exhibits potent, broadly neutralizing activity. Res. Virol. 1991, 142, 247-259.
9. 9 Cordell, J., Moore, J. P., Dean, C. J., Klasse, P. J., Weiss, R. A. and McKeating, J. A. Rat monoclonal antibodies to nonoverlapping epitopes of Human Immunodeficiency Virus Type 1 gp120 block CD4 binding in vitro. Virology 1991, 185, 72-79.
10. 10 Ho, D. D., McKeating, J. A. and Li, X. L. et al. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J. Virol. 1991, 65, 489-493.
11. 11 Posner, M. R., Hideshima, T., Cannon, T., Mukherjee, M., Mayer, K. H. and Byrn, R. A. An IgG human monoclonal antibody that reacts with HIV-1/gp120, inhibits virus binding to cells, and neutralizes infection. J. Immunol. 1991, 146, 4325-4332.
12. 12 Pinter, A., Honnen, W. J., Racho, M. E. and Tilley, S. A. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates. AIDS Res. Hum. Retroviruses 1993, 9, 985-996.
13. 13 VanCott, T. C., Polonis, V. R., Loomis, L. D., Michael, N. L., Nara, P. L. and Birx, D. L. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res. Hum. Retroviruses 1995, 11, 1379-1391.
14. 14 Bou-Habib, D. C., Roderiquez, G., Oravecz, T., Berman, P. W., Lusso, P. and Norcross, M. A. Cryptic nature of envelope V3 region epitopes protects primary monocytropic human immunodeficiency virus type 1 from antibody neutralization. J. Virol. 1994, 68, 6006-6013.
15. 15 Sullivan, N., Sun, Y., Li, J., Hofmann, W. and Sodroski, J. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J. Virol. 1995, 69, 4413-4422.
16. 16 Schutten, M., Andeweg, A. C., Bosch, M. L. and Osterhaus, A. D. M. E. Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1. Scand. J. Immunol. 1995, 41, 18-22.
17. 17 Burton, D. R., Pyati, J. and Koduri, R. et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266, 1024-1027.
18. 18 Trkola, A., Pomales, A. B. and Yuan, H. et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 1995, 69, 6609-6617.
19. 19 Conley, A. J., II, J. A.K. and Boots, L. J. et al. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc. Natl. Acad. Sci. USA 1994, 91, 3348-3352.
20. 20 Muster, T., Steindl, F. and Purtscher, M. et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 1993, 67, 6642-6647.
21. 21 Muster, T., Guinea, R. and Trkola, A. et al. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J. Virol. 1994, 68, 4031-4034.
22. 22 Trkola, A., Purtscher, M. and Muster, T. et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 1996, 70, 1100-1108.
23. 23 Mascola, J. R., Louder, M. K., VanCott, T. C., Sapan, C. V., Lambert, J. S., Muenz, L. R., Bunow, B. Birx, D. and Robb, M. I. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J. Virol. 1997, 71, 7198-206.
24. 24 Fung, M. S. C., Sun, C. R. Y. and Gordon, W. L. et al. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J. Virol. 1992, 66, 848-856.
25. 25 Ho, D. D., Fung, M. S. C. and Cao, Y. et al. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 8949-8952.
26. 26 McKeating, J. A., Shotton, C. and Cordell, J. et al. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120. J. Virol. 1993, 67, 4932-4944.
27. 27 Moore, J. P., Sattentau, Q. J. and Yoshiyama, H. et al. Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains. J. Virol. 1993, 67, 6136-6151.
28. 28 Pincus, S. H., Messer, K. G., Nara, P. L., Blattner, W. A., Colclough, G. and Reitz, M. Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers. J. Clin. Invest. 1994, 93, 2505-2513.
29. 29 Warrier, S., Pinter, A., Honnen, W. J., Girard, M., Muchmore, E. and Tilley, S. A. A novel glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent neutralizing chimpanzee monoclonal antibody. J. Virol. 1994, 68, 4636-4642.
30. 30 Wu, Z., Kayman, S. C. and Revesz, K. et al. Characterization of neutralization epitopes in the V2 region of HIV-1 gp120: role of conserved glycosylation sites in the correct folding of the V1/V2 domain. J. Virol. 1995, 69, 2271-2278.
31. 31 Honnen, W. J., Wu, Z., Kayman, S. C., Pinter, A., (Eds.), Potent neutralization of a macrophage-tropic HIV-1 isolate by antibodies against the V1/V2 domain of gp120. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1996, pp. 289-297.
32. 32 Gorny, M. K., Moore, J. P. and Conley, A. J. et al. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of HIV-1. J. Virol. 1994, 68, 8312-8320.
33. 33 Westervelt, P., Trowbridge, D. B. and Epstein, L. G. et al. Macrophage tropism determinants of human immunodeficiency virus type I in vivo. J. Virol. 1992, 66, 2577-2582.
34. 34 Chowdhury, I. H., Potash, M. J. and Volsky, D. J. Redefinition of tropism of common macrophage-tropic human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 1995, 11, 1467-1471.
35. 35 Graham, F. L., Smiley, J., Russel, W. C. and Nairn, R. Characterization of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 1977, 36, 59-72.
36. 36 Gartner, S., Markovits, P., Markovitz, D. M., Kaplan, M. H., Gallo, R. C. and Popovic, M. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 1986, 233, 215-219.
37. 37 Gao, F., Morrison, S. G. and Robertson, D. L. et al. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. J. Virol. 1996, 70, 1651-1667.
38. 38 Vijh-Warrier, S., Pinter, A., Honnen, W. J. and Tilley, S. A. Synergistic neutralization of HIV-1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site. J. Virol. 1996, 70, 4466-4473.
39. 39 Conley, A. J., Gorny, M. K. and II, J. A. K. et al. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J. Virol. 1994, 68, 6994-7000.
40. 40 Arthos, J., Deen, K. C. and Chaikin, M. A. et al. Identification of the residues in human CD4 critical for the binding of HIV. Cell 1989, 57, 469-481.
41. 41 Kayman, S. C., Wu, Z., Revesz, K., Chen, H.-C., Kopelman, R. and Pinter, A. Presentation of native epitopes in the V1/V2 and V3 domains of HIV-1 gp120 by fusion glycoproteins containing fragments of gp120. J. Virol. 1994, 68, 400-410.
42. 42 Wang, N., Zhu, T. and Ho, D. D. Sequence diversity of V1 and V2 domains of gp120 from human immunodeficiency virus type 1: lack of correlation with viral phenotype. J. Virol. 1995, 69, 2708-2715.
43. 43 Myers, G., Korber, B., Berzofsky, J., Smith, R. F., Pavlakis, G. N., Human Retroviruses and AIDS Database. Los Alamos Laboratory, Los Alamos, New Mexico 1992.
44. 44 Bebbington, C. R., Renner, G., Thomson, S., King, D., Abrams, D. and Yarrangton, G. T. High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology 1992, 10, 169-175.
45. 45 Tilley, S. A., Honnen, W. J., Racho, M. E., Hilgartner, M. and Pinter, A. A human monoclonal antibody against the CD4 binding site of HIV-1 gp120 exhibits potent, broadly neutralizing activity. Res. Virol. 1991, 142, 247-259.
46. 46 Daar, E. S., Li, X. L., Moudgil, T. and Ho, D. D. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc. Natl. Acad. Sci. USA 1990, 87, 6574-6578.
47. 47 Gomatos, P. J., Stamatos, N. M. and Gendelman, H. E. et al. Relative inefficiency of soluble recombinant CD4 for inhibition of infection by monocyte-tropic HIV in monocytes and T cells. J. Immunol. 1990, 144, 4183-4188.
48. 48 Hanson, C. V. Measuring vaccine-induced HIV neutralization: Report of a Workshop. AIDS Res. Hum. Retroviruses 1994, 10, 645-648.
49. 49 Mascola, J., Weislow, O. and Snyder, S. et al. Neutralizing antibody activity in sera from human immunodeficiency virus type 1 vaccine recipients from the AIDS Vaccine Clinical Trials Network. AIDS Res. Hum. Retroviruses 1994, 10(Suppl. 2), S55.
50. 50 Ashkenazi, A., Smith, D. H. and Marsters, S. A. et al. Resistance of primary HIV-1 isolates to soluble CD4 is independent of CD4-gp120 binding affinity. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 7056-7060.
51. 51 Sawyer, L. S. W., Wrin, M. T. and Crawford-Miksza, L. et al. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J. Virol. 1994, 68, 1342-1349.
52. 52 Guo, M. M. L. and Hildreth, J. E. K. HIV acquires functional adhesion receptors from host cells. AIDS Res. Hum. Retroviruses 1995, 11, 1007-1013.
53. 53 Hildreth, J. E. K. and Orentas, R. J. Involvement of a leukocyte adhesion receptor (LFA-1) in HIV-induced syncytium formation. Science 1989, 244, 1075
54. 54 Haynes, B. F., Pantaleo, G. and Fauci, A. S. Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996, 271, 324-328.